The Wall Street Transcript Interviews Nutra Pharma Chairman and CEO

PLANTATION, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC.OB), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J Deitsch, has been interviewed for the Pharmaceutical Issue of The Wall Street Transcript.

“With the impending launch of our first biopharmaceutical product, Cobroxin, and our transition from a research and development stage biotechnology company into a revenue-producing company, it is now more important than ever that we share our story with the investment community,” explained Mr. Deitsch. “As a highly-respected financial publication, The Wall Street Transcript provides the perfect outlet to communicate with retail and institutional investors,” he added.

In the interview, Mr. Deitsch discusses Nutra Pharma's launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain. In addition, he outlines the company’s recent accomplishments and the company’s growth opportunities with its drug discovery pipeline and potential strategic acquisitions.

The Wall Street Transcript is one of the country’s leading financial publications, reaching over 200,000 readers each month through its website and its printed magazine. Its subscriber base represents some of the top money managers, investment brokers, and corporations in the United States. The Pharmaceutical Issue, which features the interview with Mr. Deitsch, will be published and available in November 2009.